Skip to content
Medical Health Aged Care

Older cancer survivors face elevated risk of stroke and heart attack: study

Monash University 2 mins read

Older cancer survivors face a higher risk of stroke, heart attack and hospital treatment for heart failure, especially if they had chemotherapy, Monash University research study data has revealed.

Published in the journal CANCER, researchers investigated the effects of cancer treatment on older people and found the cancer and its treatment elevated the risk of cardiovascular events.

Monash University’s Dr Suzanne Orchard and her team, including first author Jaidyn Muhandiramge, analysed data from the *ASPREE study and an embedded Cancer Treatment Substudy, which has followed adults aged 70 years and older living in the community in Australia and the US.

Participants were initially in good health and were followed over several years during which some experienced a new cancer diagnosis and/or a cardiovascular disease event.

Previous research has observed cardiovascular diseases, such as stroke and heart attacks, after cancer treatment, but this is the first time the effects of different types of cancer and treatment types has been analysed.

Of the 15,454 participants, 1,392 developed cancer over an average 4.6 years.

Rates for stroke, heart attack and hospital admission for heart failure were twice as high in those who developed cancer compared with those who didn’t: 20.8 versus 10.3 events per 1,000 person-years. The elevated risk remained even after accounting for traditional cardiovascular disease risk factors.

Cardiovascular disease incidence following cancer diagnosis was greatest in patients with metastatic, blood and lung cancers. Chemotherapy was associated with twice the risk of cardiovascular disease events compared to other cancer therapies.

The results for other systemic therapies such as hormonal therapy, targeted therapy, immunotherapy and radiation therapy were inconclusive, although thoracic radiation is known to elevate risk. Aspirin did not impact cardiovascular disease incidence after cancer in this study.

Dr Orchard said as more people survived cancer, many faced long-term effects of the disease and its therapies. “The results underline how important early screening and prevention are in avoiding and minimising cardiovascular events after cancer diagnosis and treatment,” she said.

“It’s positive that more people are surviving cancer and living a long life. But it means we have a growing cohort of older people who could be at risk of health conditions related to the illness itself as well as from its treatment.

“This study adds to the growing body of data that shows those who have experienced cancer and cancer treatment face elevated risk of cardiovascular disease. While this is unwelcome news for cancer patients, the cardiovascular risk can be mitigated by early screening and preventative measures.

“More research is now needed to protect cancer survivors’ cardiovascular and general health.”


URL Upon Publication: http://doi.wiley.com/10.1002/cncr.35503

*About ASPREE
ASPREE (ASPirin in Reducing Events in the Elderly) was a large primary prevention aspirin trial in more than 19,000 participants in Australia and the US, mostly aged 70 years and older, and continues today as a longitudinal study.  Most ASPREE participants, who self-reported transport-related walking in the ALSOP (ASPREE Longitudinal Study of Older Persons) questionnaires sub-study, did so within 6-9 months of enrolment. The ASPREE project is funded by the National Institutes of Health (USA) and the NHMRC (Australia) and is led by Monash University in Australia and the Berman Center for Outcomes & Clinical Research in the US. Visit: https://aspree.org/aus/ 

For media enquiries please contact:

 

Monash University

Cheryl Critchley – Media and Communications Manager (medical)
E:
cheryl.critchley@monash.edu

T: +61 (0) 477 571 442

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: 
media@monash.edu
T: +61 (0) 3 9903 4840

 

***ENDS***

 

More from this category

  • Medical Health Aged Care
  • 17/02/2025
  • 11:51
Monash University

Monash Expert: Landmark approval of weight loss drug for heart disease

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The Therapeutic Goods Administration (TGA) has granted approval for semaglutide 2.4 mg (sold as Wegovy) to be used as a complementary therapy for reducing major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The approval follows findings from the SELECT trial, an international study involving more than 17,000 participants across 41 countries, including Australia. Results published in late 2023 showed that Wegovy reduced cardiovascular events by 20 percent in people…

  • Medical Health Aged Care
  • 17/02/2025
  • 10:11
Smith & Nephew UK Ltd

Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand

First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair*After anchor insertionSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE◊ Adjustable Achilles Reconstruction and ULTRABRACE◊ Adjustable Ankle Instability Techniques are changing the way foot & ankle surgeons perform these repairs by allowing them to refine and optimise suture tension after anchor insertion.The ability to adjust tension for specific patients allows the surgeon to give the precise amount of range-of-motion…

  • CharitiesAidWelfare, Medical Health Aged Care
  • 17/02/2025
  • 06:01
Leukaemia Foundation / World's Greatest Shave

Barber to the stars Frank Ciccone is making a buzz for Australians living with blood cancer

The Leukaemia Foundation is thrilled to announce internationally acclaimed barber and men’s hairdresser Frank Ciccone as an official Hair Ambassador of its iconic World’s…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.